1 min read
Next-Generation Therapeutic Antibody Discovery from Single B-cells
By Antibody Solutions Research Team on Jan 8, 2018 1:39:00 PM
The most robust strategy for therapeutic antibody discovery continues to be through the use of immunized animals and the ability to isolate, interrogate, and/or immortalize immune B-cells. However, capturing the full repertoire of an immunized animal is a challenge that has come to the forefront, particularly as more difficult therapeutic targets have become the industry focus. Various technologies exist for immortalizing and interrogating immune B-cells, though each strategy presents distinct advantages and disadvantages. To this end, Antibody Solutions and Single Cell Technology (SCT) have launched a partnership to integrate SCT’s pioneering single B-cell analysis technology with Antibody Solutions’ comprehensive antibody discovery platform.
Topics: antibody discovery Posters Immune B-cells
Filter by Keyword
- Posters (20)
- Publications (14)
- therapeutic monoclonal antibodies (4)
- Multi-pass transmembrane (3)
- Transgenic Animals (3)
- multi-meric membrane (3)
- ELISAs (2)
- Human Therapeutic Antibodies (2)
- Hybridoma (2)
- Monoclonal (2)
- SARS-CoV-2 (2)
- APOBEC3G (1)
- ARMER (1)
- ATX-GX (1)
- Alloy Therapeutics (1)
- Antibody Generation (1)
- BRCA2 (1)
- CEM15 (1)
- Cadherin-11 (1)
- Conditioned Media (1)
- Critical Reagents (1)
- Cystine Knot Peptides (1)
- D Protein (1)
- DLL4 (1)
- Fully Human (1)
- HIV-1 (1)
- HSA (1)
- IL-1 alpha (1)
- Immune B-cells (1)
- Immunization (1)
- Knottins (1)
- L-amino acids (1)
- L-selectin (1)
- LAM (1)
- LBAs (1)
- LOXL2 (1)
- McAbs (1)
- OmniAb (1)
- OmniRat (1)
- PNAd (1)
- Secretion Capture Report Web (1)
- Stereochemistry (1)
- Therapeutic Targets (1)
- Tissue Culture (1)
- VEGF-A (1)
- VEGF-C (1)
- VEGF-D (1)
- antibody discovery (1)
- carcinogenesis (1)
- lymphangioleiomyomatosis (1)
- p53 (1)
- pharmacokinetic (PK) (1)
- transgenic H2L2 mice (1)